)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Shukra Pharmaceuticals
Shukra Pharmaceuticals (524632) investor relations material
Shukra Pharmaceuticals Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary4 Nov, 2026
Executive summary
Board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026; consolidated Q2 net profit was 1,271.19 lakh and H1 net profit was 2,567.04 lakh.
Consolidated results include eight subsidiaries; their reported aggregate net losses were 329.99 lakh for Q2 and 537.13 lakh for H1, before consolidation adjustments.
Financial highlights
Consolidated Q2 revenue from operations was 4,420.38 lakh, versus 587.74 lakh in Q2 FY25; H1 revenue was 6,772.61 lakh, versus 1,126.85 lakh in H1 FY25.
Consolidated Q2 PBT was 1,782.84 lakh and net profit 1,271.19 lakh, versus 19.84 lakh and 237.81 lakh, respectively, in Q2 FY25.
Consolidated H1 PBT was 3,600.02 lakh and net profit 2,567.04 lakh, versus 157.16 lakh and 340.77 lakh in H1 FY25; H1 basic and diluted EPS were ₹0.58.
Standalone Q2 revenue from operations was 4,420.38 lakh, PBT 2,112.85 lakh and net profit 1,601.20 lakh; H1 net profit was 3,104.18 lakh and EPS ₹0.71.
Segment performance
Consolidated Q2 segment revenue was 3,226.93 lakh for Shukra Pharmaceutical and 1,250.65 lakh for Shukra MedTech; segment results before tax and interest were 1,506.40 lakh and 309.66 lakh, respectively.
Consolidated H1 segment revenue was 5,633.13 lakh for Shukra Pharmaceutical and 1,250.65 lakh for Shukra MedTech; respective segment results before tax and interest were 3,366.53 lakh and 309.66 lakh.
Shukra MedTech segment naming became effective October 1, 2025, so the current segment period has no corresponding MedTech segment in the prior-year comparative.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Shukra Pharmaceuticals
- Sales and exports surged, but higher depreciation cut profit as injectable expansion advanced.524632
Q4 96/97 - Sales grew 18%, profit rose, and injectable production was poised to begin amid operating cash outflow.524632Q4 97/98
- Sales and exports surged as expansion funding coincided with negative operating cash flow.524632Q4 99/00
- Turnover rose 22.72%; injection-plant launch awaited regulatory approval.524632Q4 98/99
- Higher sales, lower PAT after a ₹5.65m write-off, and restructuring define FY16.524632Q4 15/16
- Revenue surged, but profit collapsed amid qualified audit and compliance concerns.524632Q4 19/20
- Revenue and profit surged; net debt turned negative and a ₹1 dividend was proposed.524632Q4 23/24
- FY23 earnings surged as export growth advanced alongside higher receivables and tax exposure.524632Q4 22/23
- A bank settlement lifted FY12 profit despite declining revenue and restructuring pressures.524632Q4 11/12
Next Shukra Pharmaceuticals earnings date
Q3 26/2712 Feb, 2027
Shukra Pharmaceuticals
Next Shukra Pharmaceuticals earnings date
Q3 26/2712 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Shukra Pharmaceuticals Limited is a pharmaceutical company involved in the manufacturing and marketing of medicinal formulations. The company produces a variety of dosage forms, including tablets, capsules, and oral liquids, catering to different therapeutic segments. It offers its products for domestic consumption and may also engage in contract manufacturing and third-party production services. Shukra Pharmaceuticals Limited operates in accordance with industry quality standards to support its pharmaceutical operations. The company is headquartered in Ahmedabad, India, and its shares are listed on the BSE.